SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Paul Tran who wrote (239)9/18/1998 2:37:00 PM
From: Platter  Respond to of 656
 
Immunex Corp. (IMNX) 53 3/8 +7/8: Adams Harkness maintains "buy" rating on biopharmaceutical company after an FDA panel gave thumbs up to Enbrel product for the treatment of rheumatoid arthritis; believes that Enbrel is a pivotal event for IMNX as sales could drive the company to dramatic profitability in the coming years; if approved for marketing by FDA, the drug could be launched in November.....From Briefing.com



To: Paul Tran who wrote (239)11/13/1998 1:09:00 PM
From: Henry Niman  Read Replies (2) | Respond to of 656
 
I have linked a summary of the BBRS Conference Call on the ACR meeting to the TNF Inhibitor table on the New Therapeutics page at
biocognizance.com (they primarily discuss Remicade and Enbrel)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News